Group 1 - The core viewpoint of the article is that Zhengda Enterprise International (03839.HK) reported a significant revenue increase of 74.1% to $535.9 million for the fiscal year ending December 31, 2025, compared to $307.7 million in 2024, primarily driven by its biotechnology business [1] - The substantial revenue growth is attributed to the successful implementation of key strategies focused on developing large customer sales, with a notable contribution from the growth of immunobiological products [1] - The overall gross profit margin decreased from 15.9% in 2024 to 14.4% in 2025, indicating a shift in profitability despite revenue growth [1] Group 2 - The company's profit attributable to shareholders for 2025 was $32.1 million, up from $11.2 million in 2024, reflecting significant growth in the biotechnology segment [1]
正大企业国际(03839.HK)2025年净利润为3210万美元 同比增长约186.6%